相关实验视频
Updated: Jul 8, 2025

A Novel Method: Super-selective Adrenal Venous Sampling
Published on: September 15, 2017
口服富洛塞米德试验对初级阿尔多斯特罗尼斯症诊断的有效性
Thais C Freitas1, Ana Alice W Maciel1, Gustavo F C Fagundes1
1Divisão de Endocrinologia e Metabologia, Hospital das Clínicas, Unidade de Adrenal, Laboratório de Endocrinologia Molecular e Celular LIM/25, Faculdade de Medicina da Universidade de São Paulo, São Paulo, 05403-000, Brazil.
口服富洛塞米德测试提供了一种安全有效的方法来诊断原发性阿尔多斯特主义 (PA). 这种新测试在识别PA方面显示出高准确性,简化了患者的调查.
科学领域:
- 内分泌学 在内分泌学.
- 临床诊断 临床诊断 临床诊断
背景情况:
- 确认性测试对于诊断原发性阿尔多斯特主义 (PA) 是至关重要的.
- 目前的PA诊断测试往往很费力,并且由于相关风险需要住院治疗.
研究的目的:
- 为了评估口服富洛塞米德测试对原发性阿尔多斯特主义 (PA) 的诊断疗效.
主要方法:
- 在64名PA患者和22名对照组中对80毫克口服富罗塞米德的前性评估.
- 直接宁度 (DRC) 测量在试验前和2,3小时后口服罗塞米德.
- 口服富罗西米德试验与富罗西米德直立试验 (FUT) 和盐水输液试验 (SIT) 或卡普托普里尔挑战试验 (CCT) 相比.
主要成果:
- 在2小时内,DCR切线为7.6μU/mL,产生92%的灵敏度,82%的特异性和90%的准确性.
- 除了低氨酸高血压的对照,在2小时后的DRC切断值为10μU/mL,显示了95.3%的灵敏度,93.7%的特异性和95%的准确性.
- 口服罗塞米德试验与FUT具有很高的一致性 (97%),并且耐受性良好,没有报告的低血压.
结论:
- 口服富洛塞米德测试是一种安全且耐受性良好的初级阿尔多斯特症 (PA) 诊断策略.
- 这种测试为PA调查提供了有效的替代方案,可能减少对医院环境的需求.
相关概念视频
Heart Failure Drugs: Diuretics
Antihypertensive Drugs: Potassium-Sparing Diuretics
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Antihypertensive Drugs: Direct Renin Inhibitors
Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...

